KR19990082463A
(en)
|
1996-02-13 |
1999-11-25 |
돈 리사 로얄 |
Quinazolin derivatives as vascular endothelial growth factor inhibitors
|
CN1116286C
(en)
|
1996-03-05 |
2003-07-30 |
曾尼卡有限公司 |
4-anilinoquinazoline derivatives
|
GB9707800D0
(en)
|
1996-05-06 |
1997-06-04 |
Zeneca Ltd |
Chemical compounds
|
ATE300521T1
(en)
|
1996-09-25 |
2005-08-15 |
Astrazeneca Ab |
QUINOLINE DERIVATIVES THAT DELAY THE EFFECT OF GROWTH FACTORS LIKE VEGF
|
GB9718972D0
(en)
|
1996-09-25 |
1997-11-12 |
Zeneca Ltd |
Chemical compounds
|
GB9704948D0
(en)
|
1997-03-11 |
1997-04-30 |
Knoll Ag |
Therapeutic agents
|
KR20000076426A
(en)
*
|
1997-03-19 |
2000-12-26 |
스타르크, 카르크 |
Pyrrolo[2,3-D]Pyrimidines and Their Use as Tyrosine Kinase Inhibitors
|
US7863444B2
(en)
|
1997-03-19 |
2011-01-04 |
Abbott Laboratories |
4-aminopyrrolopyrimidines as kinase inhibitors
|
WO1999010349A1
(en)
|
1997-08-22 |
1999-03-04 |
Zeneca Limited |
Oxindolylquinazoline derivatives as angiogenesis inhibitors
|
PA8474101A1
(en)
|
1998-06-19 |
2000-09-29 |
Pfizer Prod Inc |
PYROLEUM [2,3-D] PIRIMIDINE COMPOUNDS
|
JP4666762B2
(en)
|
1998-06-19 |
2011-04-06 |
ファイザー・プロダクツ・インク |
Pyrrolo [2.3-d] pyrimidine compounds
|
JP2002526500A
(en)
*
|
1998-09-18 |
2002-08-20 |
ビーエーエスエフ アクチェンゲゼルシャフト |
Pyrrolopyrimidines as protein kinase inhibitors
|
US6713474B2
(en)
|
1998-09-18 |
2004-03-30 |
Abbott Gmbh & Co. Kg |
Pyrrolopyrimidines as therapeutic agents
|
US7125875B2
(en)
|
1999-04-15 |
2006-10-24 |
Bristol-Myers Squibb Company |
Cyclic protein tyrosine kinase inhibitors
|
KR20020088406A
(en)
|
1999-09-17 |
2002-11-27 |
애보트 게엠베하 운트 콤파니 카게 |
Pyrazolopyrimidines as therapeutic agents
|
US7071199B1
(en)
|
1999-09-17 |
2006-07-04 |
Abbott Gmbh & Cco. Kg |
Kinase inhibitors as therapeutic agents
|
PT1244647E
(en)
|
1999-11-05 |
2006-10-31 |
Astrazeneca Ab |
QUINAZOLINE DERIVATIVES AS VEGF INHIBITORS
|
KR100477818B1
(en)
|
1999-12-10 |
2005-03-22 |
화이자 프로덕츠 인코포레이티드 |
PYRROLO[2,3-d]PYRIMIDINE COMPOUNDS
|
AU2000240570A1
(en)
*
|
2000-03-29 |
2001-10-08 |
Knoll Gesellschaft Mit Beschraenkter Haftung |
Pyrrolopyrimidines as tyrosine kinase inhibitors
|
PT1294724E
(en)
|
2000-06-26 |
2006-07-31 |
Pfizer Prod Inc |
COMPOUNDS PYRROLE (2,3-D) PYRIMIDINE AS IMMUNOSPRESSOR AGENTS
|
AR035885A1
(en)
|
2001-05-14 |
2004-07-21 |
Novartis Ag |
DERIVATIVES OF 4-AMINO-5-FENIL-7-CYCLLOBUTILPIRROLO (2,3-D) PYRIMIDINE, A PROCESS FOR ITS PREPARATION, A PHARMACEUTICAL COMPOSITION AND THE USE OF SUCH DERIVATIVES FOR THE PREPARATION OF A PHARMACEUTICAL COMPOSITION
|
US7301023B2
(en)
|
2001-05-31 |
2007-11-27 |
Pfizer Inc. |
Chiral salt resolution
|
CA2450777C
(en)
|
2001-08-10 |
2013-04-09 |
Novartis Ag |
Use of c-src inhibitors alone or in combination with sti571 for the treatment of leukaemia
|
GB0206215D0
(en)
|
2002-03-15 |
2002-05-01 |
Novartis Ag |
Organic compounds
|
GB0226370D0
(en)
*
|
2002-11-12 |
2002-12-18 |
Novartis Ag |
Organic compounds
|
JP2006509000A
(en)
|
2002-11-26 |
2006-03-16 |
ファイザー・プロダクツ・インク |
Method of treatment of graft rejection
|
US7429596B2
(en)
*
|
2003-06-20 |
2008-09-30 |
The Regents Of The University Of California |
1H-pyrrolo [2,3-D] pyrimidine derivatives and methods of use thereof
|
WO2005037836A2
(en)
|
2003-10-15 |
2005-04-28 |
Osi Pharmaceuticals, Inc. |
Imidazo ‘1, 5 - a ! pyrazine tyrosine kinase inhibitors
|
DK1740591T3
(en)
|
2004-04-02 |
2009-10-26 |
Osi Pharm Inc |
Heterobicyclic protein kinase inhibitors substituted with a 6,6-biocyclic ring
|
WO2005116035A1
(en)
*
|
2004-05-27 |
2005-12-08 |
Pfizer Products Inc. |
Pyrrolopyrimidine derivatives useful in cancer treatment
|
GB0512324D0
(en)
|
2005-06-16 |
2005-07-27 |
Novartis Ag |
Organic compounds
|
TW200613306A
(en)
|
2004-07-20 |
2006-05-01 |
Osi Pharm Inc |
Imidazotriazines as protein kinase inhibitors
|
US7465726B2
(en)
|
2004-08-02 |
2008-12-16 |
Osi Pharmaceuticals, Inc. |
Substituted pyrrolo[2.3-B]pyridines
|
US9512125B2
(en)
|
2004-11-19 |
2016-12-06 |
The Regents Of The University Of California |
Substituted pyrazolo[3.4-D] pyrimidines as anti-inflammatory agents
|
US7566721B2
(en)
|
2005-08-08 |
2009-07-28 |
Osi Pharmaceuticals, Inc. |
Substituted thienol[2,3-d]pyrimidines as kinase inhibitors
|
WO2007035744A1
(en)
|
2005-09-20 |
2007-03-29 |
Osi Pharmaceuticals, Inc. |
Biological markers predictive of anti-cancer response to insulin-like growth factor-1 receptor kinase inhibitors
|
AR057960A1
(en)
|
2005-12-02 |
2007-12-26 |
Osi Pharm Inc |
BICYCLE PROTEIN QUINASE INHIBITORS
|
US8575164B2
(en)
|
2005-12-19 |
2013-11-05 |
OSI Pharmaceuticals, LLC |
Combination cancer therapy
|
CA2635231C
(en)
*
|
2005-12-29 |
2014-07-15 |
Abbott Laboratories |
Protein kinase inhibitors
|
RU2008133161A
(en)
|
2006-01-13 |
2010-02-20 |
Фармасайкликс, Инк. (Us) |
Tyrosine kinase inhibitors and their use
|
DK2004654T3
(en)
|
2006-04-04 |
2013-07-22 |
Univ California |
Pyrazolopyrimidine derivatives for use as kinase antagonists
|
CA2644841C
(en)
*
|
2006-04-07 |
2013-07-16 |
Novartis Ag |
Use of c-src inhibitors in combination with a pyrimidylaminobenzamide compound for the treatment of leukemia
|
DE102006016426A1
(en)
*
|
2006-04-07 |
2007-10-11 |
Merck Patent Gmbh |
Novel cyclobutyl compounds as kinase inhibitors
|
EP2201840B1
(en)
|
2006-09-22 |
2011-11-02 |
Pharmacyclics, Inc. |
Inhibitors of Bruton's Tyrosine Kinase
|
US20120101114A1
(en)
|
2007-03-28 |
2012-04-26 |
Pharmacyclics, Inc. |
Inhibitors of bruton's tyrosine kinase
|
WO2009046448A1
(en)
|
2007-10-04 |
2009-04-09 |
Intellikine, Inc. |
Chemical entities and therapeutic uses thereof
|
US8193182B2
(en)
|
2008-01-04 |
2012-06-05 |
Intellikine, Inc. |
Substituted isoquinolin-1(2H)-ones, and methods of use thereof
|
US8703777B2
(en)
|
2008-01-04 |
2014-04-22 |
Intellikine Llc |
Certain chemical entities, compositions and methods
|
CN101965350A
(en)
|
2008-01-11 |
2011-02-02 |
纳科法尔马有限公司 |
New pyrazolo [3,4-d] pyrimidine derivatives as carcinostatic agent
|
JP5547099B2
(en)
|
2008-03-14 |
2014-07-09 |
インテリカイン, エルエルシー |
Kinase inhibitors and methods of use
|
WO2009114874A2
(en)
|
2008-03-14 |
2009-09-17 |
Intellikine, Inc. |
Benzothiazole kinase inhibitors and methods of use
|
JP2011520970A
(en)
|
2008-05-19 |
2011-07-21 |
オーエスアイ・フアーマスーテイカルズ・インコーポレーテツド |
Substituted imidazopyrazines and imidazotriazines
|
AU2009268611B2
(en)
|
2008-07-08 |
2015-04-09 |
Intellikine, Llc |
Kinase inhibitors and methods of use
|
US20110224223A1
(en)
|
2008-07-08 |
2011-09-15 |
The Regents Of The University Of California, A California Corporation |
MTOR Modulators and Uses Thereof
|
EP2307025B1
(en)
|
2008-07-16 |
2017-09-20 |
Pharmacyclics LLC |
Inhibitors of bruton's tyrosine kinase for the treatment of solid tumors
|
BRPI0917459B1
(en)
|
2008-08-20 |
2017-09-12 |
Zoetis Services Llc |
N-METHYL-1- [TRANS-4- [METHYL (7H-PYRROL [2,3-D] PYRIDOL [2,3-D] PYRIMIDINE COMPOUNDS, USE OF THESE IN THERAPY AND CRYSTALLINE AS N-METHYL-PYRIMIDIN -4-YL) AMINO] CYCLOHEXYL} METHANOSULPHONAMIDE
|
JP5731978B2
(en)
|
2008-09-26 |
2015-06-10 |
インテリカイン, エルエルシー |
Heterocyclic kinase inhibitor
|
ES2570429T3
(en)
|
2008-10-16 |
2016-05-18 |
Univ California |
Condensed Ring Heteroaryl Kinase Inhibitors
|
US8476282B2
(en)
|
2008-11-03 |
2013-07-02 |
Intellikine Llc |
Benzoxazole kinase inhibitors and methods of use
|
US20120189641A1
(en)
|
2009-02-25 |
2012-07-26 |
OSI Pharmaceuticals, LLC |
Combination anti-cancer therapy
|
EP2400990A2
(en)
|
2009-02-26 |
2012-01-04 |
OSI Pharmaceuticals, LLC |
In situ methods for monitoring the emt status of tumor cells in vivo
|
US8465912B2
(en)
|
2009-02-27 |
2013-06-18 |
OSI Pharmaceuticals, LLC |
Methods for the identification of agents that inhibit mesenchymal-like tumor cells or their formation
|
WO2010099138A2
(en)
|
2009-02-27 |
2010-09-02 |
Osi Pharmaceuticals, Inc. |
Methods for the identification of agents that inhibit mesenchymal-like tumor cells or their formation
|
EP2401614A1
(en)
|
2009-02-27 |
2012-01-04 |
OSI Pharmaceuticals, LLC |
Methods for the identification of agents that inhibit mesenchymal-like tumor cells or their formation
|
MX2011011025A
(en)
|
2009-04-20 |
2011-11-02 |
Osi Pharmaceuticals Llc |
Preparation of c-pyrazine-methylamines.
|
JP5789252B2
(en)
|
2009-05-07 |
2015-10-07 |
インテリカイン, エルエルシー |
Heterocyclic compounds and uses thereof
|
JP2013504543A
(en)
|
2009-09-10 |
2013-02-07 |
ノバルティス アーゲー |
Ether derivatives of bicyclic heteroaryls
|
US8980899B2
(en)
|
2009-10-16 |
2015-03-17 |
The Regents Of The University Of California |
Methods of inhibiting Ire1
|
CN102712648A
(en)
|
2009-11-25 |
2012-10-03 |
诺瓦提斯公司 |
Benzene-fused 6-membered oxygen-containing heterocyclic derivatives of bicyclic heteroaryls
|
US20110275644A1
(en)
|
2010-03-03 |
2011-11-10 |
Buck Elizabeth A |
Biological markers predictive of anti-cancer response to insulin-like growth factor-1 receptor kinase inhibitors
|
WO2011109584A2
(en)
|
2010-03-03 |
2011-09-09 |
OSI Pharmaceuticals, LLC |
Biological markers predictive of anti-cancer response to insulin-like growth factor-1 receptor kinase inhibitors
|
EP2544672A1
(en)
|
2010-03-09 |
2013-01-16 |
OSI Pharmaceuticals, LLC |
Combination anti-cancer therapy
|
AU2011255218B2
(en)
|
2010-05-21 |
2015-03-12 |
Infinity Pharmaceuticals, Inc. |
Chemical compounds, compositions and methods for kinase modulation
|
CA3113343A1
(en)
|
2010-06-03 |
2011-12-08 |
Pharmacyclics Llc |
Use of inhibitors of bruton's tyrosine kinase (btk) in the treatment of follicular lymphoma
|
CN102947275A
(en)
|
2010-06-17 |
2013-02-27 |
诺瓦提斯公司 |
Piperidinyl substituted 1,3-dihydro-benzoimidazol-2-ylideneamine derivatives
|
JP2013528635A
(en)
|
2010-06-17 |
2013-07-11 |
ノバルティス アーゲー |
Biphenyl-substituted 1,3-dihydro-benzimidazol-2-ylideneamine derivatives
|
EP2637669A4
(en)
|
2010-11-10 |
2014-04-02 |
Infinity Pharmaceuticals Inc |
Heterocyclic compounds and uses thereof
|
JP2014501790A
(en)
|
2011-01-10 |
2014-01-23 |
インフィニティー ファーマシューティカルズ, インコーポレイテッド |
Process for the preparation of isoquinolinone and solid form of isoquinolinone
|
US20120214830A1
(en)
|
2011-02-22 |
2012-08-23 |
OSI Pharmaceuticals, LLC |
Biological markers predictive of anti-cancer response to insulin-like growth factor-1 receptor kinase inhibitors in hepatocellular carcinoma
|
US9295673B2
(en)
|
2011-02-23 |
2016-03-29 |
Intellikine Llc |
Combination of mTOR inhibitors and P13-kinase inhibitors, and uses thereof
|
JP2014507465A
(en)
*
|
2011-03-08 |
2014-03-27 |
ノバルティス アーゲー |
Fluorophenyl bicyclic heteroaryl compounds
|
EP3597761A1
(en)
|
2011-03-09 |
2020-01-22 |
Richard G. Pestell |
Prostate cancer cell lines, gene signatures and uses thereof
|
US9896730B2
(en)
|
2011-04-25 |
2018-02-20 |
OSI Pharmaceuticals, LLC |
Use of EMT gene signatures in cancer drug discovery, diagnostics, and treatment
|
AU2012283775A1
(en)
|
2011-07-13 |
2014-01-23 |
Pharmacyclics Llc |
Inhibitors of Bruton's tyrosine kinase
|
EP2734520B1
(en)
|
2011-07-19 |
2016-09-14 |
Infinity Pharmaceuticals, Inc. |
Heterocyclic compounds and uses thereof
|
AR088218A1
(en)
|
2011-07-19 |
2014-05-21 |
Infinity Pharmaceuticals Inc |
USEFUL HETEROCICLICAL COMPOUNDS AS PI3K INHIBITORS
|
RU2014111823A
(en)
|
2011-08-29 |
2015-10-10 |
Инфинити Фармасьютикалз, Инк. |
HETEROCYCLIC COMPOUNDS AND THEIR APPLICATIONS
|
JP6342805B2
(en)
|
2011-09-02 |
2018-06-13 |
ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア |
Substituted pyrazolo [3,4-D] pyrimidine and uses thereof
|
US8377946B1
(en)
|
2011-12-30 |
2013-02-19 |
Pharmacyclics, Inc. |
Pyrazolo[3,4-d]pyrimidine and pyrrolo[2,3-d]pyrimidine compounds as kinase inhibitors
|
WO2013152252A1
(en)
|
2012-04-06 |
2013-10-10 |
OSI Pharmaceuticals, LLC |
Combination anti-cancer therapy
|
US8940742B2
(en)
|
2012-04-10 |
2015-01-27 |
Infinity Pharmaceuticals, Inc. |
Heterocyclic compounds and uses thereof
|
US9453836B2
(en)
|
2012-05-14 |
2016-09-27 |
Richard G. Pestell |
Use of modulators of CCR5 in the treatment of cancer and cancer metastasis
|
KR20190040370A
(en)
|
2012-06-04 |
2019-04-17 |
파마싸이클릭스 엘엘씨 |
Crystalline forms of a bruton's tyrosine kinase inhibitor
|
US8828998B2
(en)
|
2012-06-25 |
2014-09-09 |
Infinity Pharmaceuticals, Inc. |
Treatment of lupus, fibrotic conditions, and inflammatory myopathies and other disorders using PI3 kinase inhibitors
|
EP3550031A1
(en)
|
2012-07-24 |
2019-10-09 |
Pharmacyclics, LLC |
Mutations associated with resistance to inhibitors of bruton's tyrosine kinase (btk)
|
RU2015115631A
(en)
|
2012-09-26 |
2016-11-20 |
Дзе Риджентс Оф Дзе Юниверсити Оф Калифорния |
MODULATION IRE1
|
MX2015006168A
(en)
|
2012-11-15 |
2015-08-10 |
Pharmacyclics Inc |
Pyrrolopyrimidine compounds as kinase inhibitors.
|
JP6255038B2
(en)
|
2013-02-26 |
2017-12-27 |
トリアクト セラピューティクス,インク. |
Cancer treatment
|
US9481667B2
(en)
|
2013-03-15 |
2016-11-01 |
Infinity Pharmaceuticals, Inc. |
Salts and solid forms of isoquinolinones and composition comprising and methods of using the same
|
JP6800750B2
(en)
|
2013-08-02 |
2020-12-16 |
ファーマサイクリックス エルエルシー |
Treatment method for solid tumors
|
ES2709509T3
(en)
|
2013-08-12 |
2019-04-16 |
Pharmacyclics Llc |
Procedures for the treatment of cancer amplified by HER2
|
EP3044593A4
(en)
|
2013-09-09 |
2017-05-17 |
Triact Therapeutics, Inc. |
Cancer therapy
|
EA201690618A1
(en)
|
2013-09-30 |
2016-09-30 |
Фармасайкликс Элэлси |
BLUTON TYROSINKINASE INHIBITORS
|
PL3052485T3
(en)
|
2013-10-04 |
2022-02-28 |
Infinity Pharmaceuticals, Inc. |
Heterocyclic compounds and uses thereof
|
US9751888B2
(en)
|
2013-10-04 |
2017-09-05 |
Infinity Pharmaceuticals, Inc. |
Heterocyclic compounds and uses thereof
|
EP3060218A4
(en)
|
2013-10-25 |
2017-07-19 |
Pharmacyclics LLC |
Methods of treating and preventing graft versus host disease
|
SG11201607705XA
(en)
|
2014-03-19 |
2016-10-28 |
Infinity Pharmaceuticals Inc |
Heterocyclic compounds for use in the treatment of pi3k-gamma mediated disorders
|
WO2015143400A1
(en)
|
2014-03-20 |
2015-09-24 |
Pharmacyclics, Inc. |
Phospholipase c gamma 2 and resistance associated mutations
|
US20150320755A1
(en)
|
2014-04-16 |
2015-11-12 |
Infinity Pharmaceuticals, Inc. |
Combination therapies
|
US11920164B2
(en)
|
2014-07-30 |
2024-03-05 |
Yeda Research And Development Co. Ltd. |
Media for culturing naive human pluripotent stem cells
|
US9533991B2
(en)
|
2014-08-01 |
2017-01-03 |
Pharmacyclics Llc |
Inhibitors of Bruton's tyrosine kinase
|
JP2017523206A
(en)
|
2014-08-07 |
2017-08-17 |
ファーマサイクリックス エルエルシー |
New formulation of breton-type tyrosine kinase inhibitor
|
US9708348B2
(en)
|
2014-10-03 |
2017-07-18 |
Infinity Pharmaceuticals, Inc. |
Trisubstituted bicyclic heterocyclic compounds with kinase activities and uses thereof
|
IL315294A
(en)
|
2015-03-03 |
2024-10-01 |
Pharmacyclics Llc |
Pharmaceutical formulations of bruton's tyrosine kinase inhibitor
|
US10160761B2
(en)
|
2015-09-14 |
2018-12-25 |
Infinity Pharmaceuticals, Inc. |
Solid forms of isoquinolinones, and process of making, composition comprising, and methods of using the same
|
WO2017161116A1
(en)
|
2016-03-17 |
2017-09-21 |
Infinity Pharmaceuticals, Inc. |
Isotopologues of isoquinolinone and quinazolinone compounds and uses thereof as pi3k kinase inhibitors
|
US10919914B2
(en)
|
2016-06-08 |
2021-02-16 |
Infinity Pharmaceuticals, Inc. |
Heterocyclic compounds and uses thereof
|
SG10201912456RA
(en)
|
2016-06-24 |
2020-02-27 |
Infinity Pharmaceuticals Inc |
Combination therapies
|
JP7021356B2
(en)
|
2017-12-21 |
2022-02-16 |
ヘフェイ インスティテューツ オブ フィジカル サイエンス, チャイニーズ アカデミー オブ サイエンシーズ |
Pyrimidine derivative kinase inhibitors
|
EP3914698A1
(en)
|
2019-01-23 |
2021-12-01 |
Yeda Research and Development Co. Ltd |
Culture media for pluripotent stem cells
|
WO2021097256A1
(en)
|
2019-11-14 |
2021-05-20 |
Cohbar, Inc. |
Cxcr4 antagonist peptides
|